Literature DB >> 27312405

The Effects of Pharmacological Opioid Blockade on Neural Measures of Drug Cue-Reactivity in Humans.

Kelly E Courtney1, Dara G Ghahremani2, Lara A Ray1,2.   

Abstract

Interactions between dopaminergic and opioidergic systems have been implicated in the reinforcing properties of drugs of abuse. The present study investigated the effects of opioid blockade, via naltrexone, on functional magnetic resonance imaging (fMRI) measures during methamphetamine cue-reactivity to elucidate the role of endogenous opioids in the neural systems underlying drug craving. To investigate this question, non-treatment seeking individuals with methamphetamine use disorder (N=23; 74% male, mean age=34.70 (SD=8.95)) were recruited for a randomized, placebo controlled, within-subject design and underwent a visual methamphetamine cue-reactivity task during two blood-oxygen-level dependent (BOLD) fMRI sessions following 3 days of naltrexone (50 mg) and matched time for placebo. fMRI analyses tested naltrexone-induced differences in BOLD activation and functional connectivity during cue processing. The results showed that naltrexone administration reduced cue-reactivity in sensorimotor regions and related to altered functional connectivity of dorsal striatum, ventral tegmental area, and precuneus with frontal, visual, sensory, and motor-related regions. Naltrexone also weakened the associations between subjective craving and precuneus functional connectivity with sensorimotor regions and strengthened the associations between subjective craving and dorsal striatum and precuneus connectivity with frontal regions. In conclusion, this study provides the first evidence that opioidergic blockade alters neural responses to drug cues in humans with methamphetamine addiction and suggests that naltrexone may be reducing drug cue salience by decreasing the involvement of sensorimotor regions and by engaging greater frontal regulation over salience attribution.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27312405      PMCID: PMC5061897          DOI: 10.1038/npp.2016.99

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  51 in total

Review 1.  Incentive-sensitization and addiction.

Authors:  T E Robinson; K C Berridge
Journal:  Addiction       Date:  2001-01       Impact factor: 6.526

2.  Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications.

Authors:  L Toll; I P Berzetei-Gurske; W E Polgar; S R Brandt; I D Adapa; L Rodriguez; R W Schwartz; D Haggart; A O'Brien; A White; J M Kennedy; K Craymer; L Farrington; J S Auh
Journal:  NIDA Res Monogr       Date:  1998-03

3.  Regional cerebral blood flow changes in chronic alcoholic patients induced by naltrexone challenge during detoxification.

Authors:  A M Catafau; A Etcheberrigaray; J Perez de los Cobos; M Estorch; J Guardia; A Flotats; L Bernà; C Marí; M Casas; I Carrió
Journal:  J Nucl Med       Date:  1999-01       Impact factor: 10.057

Review 4.  Extended-release intramuscular naltrexone (VIVITROL®): a review of its use in the prevention of relapse to opioid dependence in detoxified patients.

Authors:  Yahiya Y Syed; Gillian M Keating
Journal:  CNS Drugs       Date:  2013-10       Impact factor: 5.749

5.  Subjective responses to alcohol in the lab predict neural responses to alcohol cues.

Authors:  Kelly E Courtney; Lara A Ray
Journal:  J Stud Alcohol Drugs       Date:  2014-01       Impact factor: 2.582

6.  Cocaine cues and dopamine in dorsal striatum: mechanism of craving in cocaine addiction.

Authors:  Nora D Volkow; Gene-Jack Wang; Frank Telang; Joanna S Fowler; Jean Logan; Anna-Rose Childress; Millard Jayne; Yeming Ma; Christopher Wong
Journal:  J Neurosci       Date:  2006-06-14       Impact factor: 6.167

Review 7.  Addiction, compulsive drug seeking, and the role of frontostriatal mechanisms in regulating inhibitory control.

Authors:  Jodie Feil; Dianne Sheppard; Paul B Fitzgerald; Murat Yücel; Dan I Lubman; John L Bradshaw
Journal:  Neurosci Biobehav Rev       Date:  2010-03-17       Impact factor: 8.989

8.  Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study.

Authors:  Lara A Ray; Kent E Hutchison
Journal:  Arch Gen Psychiatry       Date:  2007-09

9.  Effects of naltrexone on adolescent alcohol cue reactivity and sensitivity: an initial randomized trial.

Authors:  Robert Miranda; Lara Ray; Alexander Blanchard; Elizabeth K Reynolds; Peter M Monti; Thomas Chun; Alicia Justus; Robert M Swift; Jennifer Tidey; Chad J Gwaltney; Jason Ramirez
Journal:  Addict Biol       Date:  2013-03-13       Impact factor: 4.280

10.  Tools of the trade: psychophysiological interactions and functional connectivity.

Authors:  Jill X O'Reilly; Mark W Woolrich; Timothy E J Behrens; Stephen M Smith; Heidi Johansen-Berg
Journal:  Soc Cogn Affect Neurosci       Date:  2012-05-07       Impact factor: 3.436

View more
  10 in total

1.  A preliminary randomized clinical trial of naltrexone reduces striatal resting state functional connectivity in people with methamphetamine use disorder.

Authors:  Milky Kohno; Laura E Dennis; Holly McCready; Daniel L Schwartz; William F Hoffman; P Todd Korthuis
Journal:  Drug Alcohol Depend       Date:  2018-09-21       Impact factor: 4.492

2.  Naltrexone Acutely Enhances Connectivity Between the Ventromedial Prefrontal Cortex and a Left Frontoparietal Network.

Authors:  Amanda Elton; Samantha Dove; Cory N Spencer; Donita L Robinson; Charlotte A Boettiger
Journal:  Alcohol Clin Exp Res       Date:  2019-04-08       Impact factor: 3.455

3.  Executive function moderates naltrexone effects on methamphetamine-induced craving and subjective responses.

Authors:  Aaron C Lim; Erica N Grodin; Rejoyce Green; Alexandra Venegas; Lindsay R Meredith; Kelly E Courtney; Nathasha R Moallem; Philip Sayegh; Edythe D London; Lara A Ray
Journal:  Am J Drug Alcohol Abuse       Date:  2020-04-28       Impact factor: 3.829

4.  Prefrontal fNIRS-based clinical data analysis of brain functions in individuals abusing different types of drugs.

Authors:  Xuelin Gu; Banghua Yang; Shouwei Gao; Lin Feng Yan; Ding Xu; Wen Wang
Journal:  J Biomed Semantics       Date:  2021-11-25

5.  Effects of methamphetamine on neural responses to visual stimuli.

Authors:  Kathryne Van Hedger; Sarah K Keedy; Kathryn E Schertz; Marc G Berman; Harriet de Wit
Journal:  Psychopharmacology (Berl)       Date:  2019-01-02       Impact factor: 4.530

6.  Naltrexone moderates the relationship between cue-induced craving and subjective response to methamphetamine in individuals with methamphetamine use disorder.

Authors:  Daniel J O Roche; Matthew J Worley; Kelly E Courtney; Spencer Bujarski; Edythe D London; Steven Shoptaw; Lara A Ray
Journal:  Psychopharmacology (Berl)       Date:  2017-03-29       Impact factor: 4.415

7.  Naltrexone modulates dopamine release following chronic, but not acute amphetamine administration: a translational study.

Authors:  N Jayaram-Lindström; J Guterstam; J Häggkvist; M Ericson; T Malmlöf; B Schilström; C Halldin; S Cervenka; T Saijo; A-L Nordström; J Franck
Journal:  Transl Psychiatry       Date:  2017-04-25       Impact factor: 6.222

Review 8.  A Scoping Review on Cue Reactivity in Methamphetamine Use Disorder.

Authors:  Lee Seng Esmond Seow; Wei Jie Ong; Aditi Hombali; P V AshaRani; Mythily Subramaniam
Journal:  Int J Environ Res Public Health       Date:  2020-09-07       Impact factor: 3.390

9.  Opioid antagonism modulates wanting-related frontostriatal connectivity.

Authors:  Alexander Soutschek; Susanna C Weber; Thorsten Kahnt; Boris B Quednow; Philippe N Tobler
Journal:  Elife       Date:  2021-11-11       Impact factor: 8.140

10.  FMRI-based prediction of naltrexone response in alcohol use disorder: a replication study.

Authors:  Patrick Bach; Georg Weil; Enrico Pompili; Sabine Hoffmann; Derik Hermann; Sabine Vollstädt-Klein; Falk Kiefer; Karl Mann; Wolfgang H Sommer
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2021-04-21       Impact factor: 5.270

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.